The San Francisco Bay Area — South San Francisco in particular — is one of the two largest biotech clusters in the world, alongside Boston and Cambridge. Most companies here are venture-backed, many are pre-commercial, and a large share own no manufacturing plant at all. They design the science and outsource the making, testing and often the running of trials.
That model changes what validation means. A virtual biotech has fewer systems of its own to validate, but it carries full regulatory responsibility for work done by other people. This guide covers the priorities that are specific to that model, and the transition from clinical to commercial where most gaps appear. It complements validation for Boston and Cambridge biotech.
You outsource the work, not the responsibility
When a CDMO manufactures your product or a CRO runs your trial, the regulator still holds you — the sponsor or marketing authorisation holder — accountable. ICH E6(R3) is explicit on sponsor oversight in clinical work, and GMP is equally clear that a contract giver remains responsible for the product.
For validation, this means your main job is often supplier oversight rather than system testing: qualifying the CDMO and CRO, confirming their systems are validated, defining in a quality agreement who does what, and reviewing their data. See supplier qualification.
The common gap: a quality agreement signed early, when the company was small, that never gets updated as the programme scales. By Phase 3 it no longer describes reality.
Validating a SaaS-heavy stack
Bay Area biotechs tend to run almost entirely on cloud software: an electronic trial master file, a quality management system, document control, LIMS or ELN from a SaaS vendor, and often an EDC system through the CRO. Each one that supports a GxP decision needs validation — even though you do not host it.
- Leverage vendor evidence properly. A qualified supplier's testing can reduce your effort, but relying on it is your documented decision. See cloud and SaaS validation.
- Plan for vendor releases. SaaS vendors update on their schedule, not yours. You need a process to assess each release for GxP impact — the part most small teams do not have.
- Watch the integrations. The link between your ELN and LIMS, or between the CRO's EDC and your data warehouse, is where records lose attribution.
- Size effort by risk. A document system holding controlled procedures and a scheduling tool do not need the same rigour. See GxP risk assessment.
The clinical-to-commercial jump
Most validation gaps surface at one moment: the move from late-stage trials to a marketing application. A pre-approval inspection looks at whether the company is ready to be a commercial manufacturer — and many small companies discover their quality system was built for a research organisation.
The typical issues are predictable:
- Systems adopted quickly in the early years, never formally validated or validated only lightly.
- No named system owner, so periodic reviews and access reviews have lapsed. See GxP roles and responsibilities.
- Training records that do not match the current SOP versions.
- Data spread across the CRO, the CDMO and internal tools, with no clear single source of truth.
The fix is to start preparation twelve to eighteen months before the planned filing, not after the submission date is set. Inspection readiness covers what that looks like.
Doing this with a small team
A typical Bay Area biotech has a quality team of a handful of people covering everything. That makes efficiency the real constraint. Three habits help most: keep one system inventory with a GxP-relevance rationale for each entry; validate in proportion to risk rather than producing the same heavy package for every tool; and automate the documentation-heavy parts of the work.
That last one is where GxP AI is gaining ground with small teams — drafting validation documents and traceability for a qualified person to review and approve, so a small team can cover a growing system estate without falling behind. The wider tooling picture is in GxP software.
Where to go next
Explore GxP Copilot for AI-native validation, TraceDraft for source-traceable clinical documentation, or book a demo to see either on your own data.